AOCI at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's AOCI?
- Ionis Pharmaceuticals (IONS) reported AOCI of -$31.02M in Q1 2026.
- How has Ionis Pharmaceuticals's AOCI changed year-over-year?
- Ionis Pharmaceuticals's AOCI decreased by 7.2% year-over-year, from -$28.95M to -$31.02M.
- What is the long-term trend for Ionis Pharmaceuticals's AOCI?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's AOCI has grown at a 3.7% compound annual growth rate (CAGR), from -$21.07M to -$25.28M.
- What does AOCI mean?
- The cumulative total of unrealized gains and losses that bypass the income statement.
- How do you interpret AOCI?
- Fluctuations often signal changes in market interest rates, currency exchange volatility, or the fair value of investment portfolios.
- How does AOCI compare across companies?
- Common in companies with significant international operations or large investment portfolios.